Vaccines are undergoing their most significant technological transformation since the introduction of recombinant DNA technology. The COVID-19 pandemic validated mRNA vaccine technology at population scale. Pfizer’s Abrysvo and GSK’s Arexvy launched simultaneously as the first RSV vaccines for older adults, generating combined revenues of several billion dollars in their first full years.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• mRNA Platform Development
• RSV Vaccines
• Influenza Vaccines
• COVID-19 Vaccines
• Pneumococcal Vaccines
• Cancer Vaccines
• Pandemic Preparedness
Table of Contents
1. Executive Summary
2. Market Overview
3. mRNA Platform Development
4. RSV Vaccines
5. Influenza Vaccines
6. COVID-19 Vaccines
7. Pneumococcal Vaccines
8. Cancer Vaccines
9. Pandemic Preparedness
10. Competitive Landscape
11. Regional Market Analysis
12. Strategic Conclusions and Recommendations
13. Appendix
List of Tables
Table 1. Market Overview and Leading Products 2025
Table 2. Competitive Landscape by Sub-Segment 2025
Table 3-8. Topic-Specific Analysis Tables
Table 3. Leading Companies — Portfolio and Pipeline Assessment 2025
Table 4. M&A and Licensing Activity 2023-2025
Table 5. Regional Market Analysis
Table 6. Key Risks and Mitigation Strategies
Companies Profiled
Pfizer
Moderna
GSK
Sanofi
AstraZeneca
Johnson & Johnson
BioNTech
Seqirus
Bavarian Nordic
